ClinicalTrials.gg
CompletedNCT02235194Updated Sep 24, 2019

Effects of an Amino Acid and Chromium-picolinate Containing Drink on Glucose Metabolism

An interventional study of Amino Acid and chromium-picolinate containing drink and Placebo Drink in Type 2 Diabetes and Prediabetes, sponsored by Stoffwechselzentrum Rhein - Pfalz. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-09-24.

Sponsored by Stoffwechselzentrum Rhein - Pfalz · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 756 studies in Diabetes Mellitus, Type 2 with a site in Germany — 46 open to participants now, 67 under way, 23 of them phase 3. Diabetes Mellitus, Type 2 · Germany.

Enrollment
636th of 688
20 · median 218
Started
2014
with 27 others
No phase
87 of 756
9 open now
Registered
455th of 756
by date

Among the 756 studies in Diabetes Mellitus, Type 2 with a site in Germany, this one is the 636th largest by enrollment of the 688 interventional ones that give a count, is one of 28 that started in 2014, is one of 87 with no phase, and was the 455th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

46 of the 756 studies in Diabetes Mellitus, Type 2 with a site in Germany are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 756 studies in Diabetes Mellitus, Type 2 with a site in Germany, or all of them as a file.
02

Study summary

It has previously been shown in healthy overweight subjects, that table water including a defined amount of amino acids and chromium can decrease the postprandial glucose and insulin response. In this study, the effect of this table water on glucose excursions after a test meal containing a defined amount of available carbohydrates, protein and fat will be studied in patients with early type 2 diabetes or prediabetes according to guidelines that are treated with dietary measures or metformin only. The study will be conducted in a cross -over design, double blinded and placebo controlled including 20 participants. The primary endpoint of the study is the incremental area under the curve for plasma glucose (iAUCgluc) within 180 minutes after ingestion of the meal.

03

Conditions studied

  • Type 2 Diabetes
  • Prediabetes
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Early Type 2 Diabetes (i.e. on Metformin or diet only)
  • Prediabetes (i.e. FPG 100-125 mg/dl or IGT 2h PG in OGTT 140-199 mg/dl)
  • \< 7%
  • 28,0-39,9 kg/m²

Exclusion criteria

Exclusion Criteria

  • Any antidiabetic medication other than metformin
  • Psychiatric Disease
  • Acute Infections
  • Alcohol or drug abuse
  • Malignant tumors or hematologic disorders
  • Heart failure III-IV
  • Acute coronary syndrome
  • Any macrovascular event within previous 3 months
  • Chronic kidney disease > Stage 3
  • Pregnancy or Lactation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Amino Acids, Chromium - Picolinate

    Verum drink containing the dietary supplements is taken with a test meal. INsulin and glucose response is documented for 180 minutes.

    Dietary Supplement: Amino Acid and chromium-picolinate containing drink · Dietary Supplement: Placebo Drink

  • Placebo comparator
    Placebo Drink

    Placebo Drink containing aroma only is taken with a test meal. INsulin and glucose response is documented for 180 minutes.

    Dietary Supplement: Amino Acid and chromium-picolinate containing drink · Dietary Supplement: Placebo Drink

Interventions

  • Dietary supplementAmino Acid and chromium-picolinate containing drink

    Amino Acid and chromium - picolinate containg water ist taken with a test meal to study efects on glucose and insulin response.

  • Dietary supplementPlacebo Drink

    Placebo drink ist taken with a test meal to study efects on glucose and insulin response.

06

What researchers measure

Primary outcomes

  1. Area under the curve for Glucose

    Area under the curve for glucose will be measured within 180 minutes after a test meal. Blood samples will be drawan at 8 timepoints during 180 minutes after ingestion of the test meal (0', 15', 30', 60', 90', 120', 150', 180').

    Time frame: 0', 15', 30', 60', 90', 120', 150', 180' post test meal

Secondary outcomes

  1. AUC for insulin

    Blood samples will be drawan at 8 timepoints during 180 minutes after ingestion of the test meal (0', 15', 30', 60', 90', 120', 150', 180').

    Time frame: 0', 15', 30', 60', 90', 120', 150', 180' post test meal

  2. Markers of inflammation

    Blood samples will be drawan at 8 timepoints during 180 minutes after ingestion of the test meal (0', 15', 30', 60', 90', 120', 150', 180'). At these timepoints markers of inflammation will be measured (i.e. hsCRP and others)

    Time frame: at 0', 15', 30', 60', 90', 120', 150', 180' post test meal

  3. markers of lipid metabolism

    Triglycerides, VLDL and other parameters of lipid metabolism are planned to be measured within 180 minutes after a test meal at 0', 15', 30', 60', 90', 120', 150', 180'.

    Time frame: 0', 15', 30', 60', 90', 120', 150', 180' post test meal

  4. Gut peptide hormones

    Area under the curve for GLP-1, ghrelin, glucagone and GIP are measured within 180 minutes after the test meal.

    Time frame: 0', 15', 30', 60', 90', 120', 150', 180' post test meal

07

Study locations

1 site
  • Stoffwechselzentrum Rhein Pfalz
    Mannheim, 68163, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2014
First posted
Sep 9, 2014
Start
Aug 2014
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Last update
Sep 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02235194
Lead sponsor
Stoffwechselzentrum Rhein - Pfalz
Responsible party
Dr. Per Humpert (Privatdozent Dr. Per M. Humpert, Stoffwechselzentrum Rhein - Pfalz) — Principal investigator
First posted
Sep 9, 2014
Start date
Aug 2014
Primary completion
Nov 2015
Completion
Nov 2015
Last update
Sep 24, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion